Biofourmis, In Business To Improve Patient Outcomes With Novel Analytics Engine

James Dargan

FDA-Approved

When your deep-tech product is cleared by the US Food and Drug Administration (FDA), a governing body responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods, and feed and veterinary products, customers have guarantees that what they’re getting is safe to use or administer, because this is what has happened for a fast-growing Boston, Massachusetts-based digital health company founded in Singapore in 2015 by Kuldeep Singh Rajput, Mark Niu and Maulik Majmudar.

So let’s take a look at the startup’s TAFF parameters:

Biofourmis and its Biovitals™ Analytics Engine is a personalized AI-powered health analytics platform unifying data and machine learning (ML) to forecast patients from acute to chronic conditions such as heart failure, oncology, acute coronary syndrome, COPD, and chronic pain.

To prove the company’s platform is the real deal, this month Biofourmis was named 2021 DPHARM Idol Disrupt Winner, an award judged by leaders in the pharma and life sciences.

“All of us, I think, recognize that technology is only one part of the solution of actually addressing these complex patient populations and their needs. The vision has always been there to say what are the services to put around that technology to really drive the outcomes that we care about.”

 — Maulik Majmudar, Co-Founder and Chief Medical Officer, Biofourmis

Biofourmis

The company’s Software as a Medical Device (SaMD) and Decentralized Clinical Trials (DCTs) have the industry excited. And the $143.6 million Biofourmis has raised in total funding over eight rounds, is a clear indicator the startup’s investors like SoftBank Vision Fund, MassMutual Ventures Southeast Asia (MMV SEA), and Sequoia Capital India are taking the founders and team seriously.

Kuldeep Singh Rajput is the first of three Co-Founders and Biofourmis’ CEO. Recognized as the “Forbes 30 Under 30”, Rajput possesses strong leadership experience with building teams, developing talents, and successfully growing, and managing strategic partnerships with global pharmaceutical manufacturers, health systems and payers.

He uses his background and experience in biomedical engineering and data from the Massachusetts Institute of Technology (MIT) to unfold his vision of “Predicting and Preventing Serious Medical Events using AI”. During his Ph.D. studies at the National University of Singapore (NUS), he built bioelectronic implants, which aim to control biological processes and treat diseases by modulating electric impulses.

An entrepreneur and investor in early-stage companies, Mark Niu is the second Co-Founder at Biofourmis and the startup’s Chief Privacy Officer, responsible for end-point security, physical and network security, as well as cloud security amongst other things. Niu received a Ph.D. in Chemical Engineering from the National University of Singapore.

The third and final Co-Founder and Chief Medical Officer at Biofourmis is Maulik Majmudar, a cardiologist by training and former Medical Officer at Amazon. Prior to joining Amazon, he was Associate Director of the Healthcare Transformation Lab at Massachusetts General Hospital, and an Assistant Professor at Harvard Medical School, where he was responsible for the identification, validation, and implementation of digital health solutions to improve care delivery as well as the patient and provider experience. While at MGH, he was awarded an education grant from the Aetna Foundation to launch a new Fellowship in Healthcare Innovation, aimed at fostering the next generation of clinician innovators.

Majmudar was also a founding member and chief clinical officer of Quanttus, Inc. a venture-backed medical wearables startup that was developing a novel wrist-based device for continuous cuffless blood pressure monitoring.

He attended Northwestern University Feinberg School of Medicine and then completed residency training in Internal Medicine at The Johns Hopkins Hospital, followed by a cardiovascular medicine fellowship at the Brigham and Women’s Hospital. He also holds two patents and has had several publications in high-impact journals, such as Nature, Circulation, JAMA, and Journal of Healthcare Delivery and Implementation Science.

With a vision to make its advanced technology to change the healthcare landscape by improving patient outcomes and lowering the cost and burden of care, Biofourmis is setting the bar high for others in the industry to follow.

Total
0
Shares
Leave a Reply
Previous Post
TQD Exclusive: ColdQuanta’s Pioneering Culture is Poised For a Bold Quantum Future

TQD Exclusive: ColdQuanta’s Pioneering Culture is Poised For a Bold Quantum Future

Next Post
Riverlane Appoints ex-White House Scientist Jake Taylor as Chief Science Officer

Riverlane Appoints ex-White House Scientist Jake Taylor as Chief Science Officer

Related Posts
The Deeptech Insider